S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Investing

Pre-Market Stock Notes (MAR 12, 2007)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

(BIIB) Biogen-Idec primary endpoint met in Phase 2 trial of Daclizumab in patients with relapsing multiple sclerosis with PDL BioPharma.
(CCOI) Cogent Communications -$0.21 EPS vs -$0.24e.
(CLMS) Calamos reported $42.9B assets under management; compared with $44.5B one month ago and $46.4B one yr ago.
(CRAY) Cray wins supercomputer order for Swiss weather service.
(CREE) Cree is paying $200M to acquire COTCO for its luminant device.
(DEPO) DepoMed files Investigational New Drug Application for Gabapentin GR for the treatment of postmenopausal hot flashes.
(DG) Dollar General being acquired by KKR for $7 Billion or $22.00 per share.
(DYAX) Dyax and Glenmark enter into funded research agreement for discovery of therapeutic antibodies.
(ECLG) eCollege expects to beat guidance before extraordinary charges.
(IMAX) Imax in joint venture with Regal Cinemas.
(MAC) Macerich offers $700M in convertible notes and will repurchase up to $75M in shares.
(PDLI) PDL BioPharma says primary endpoint met in Phase 2 trial of Daclizumab in patients with relapsing multiple sclerosis with Biogen-Idec.
(QDEL) Quidel announced $25 Million for share buybacks.
(RDCM) Radcom CEO retiring.
(SGP) Schering Plough is paying some $14 Billion to purchase the animal health care business of Akzo Nobel N.V.
(SIE) Sierra Health trading up 14% on UNH buyout of $43.50 per share.
(STP) Suntech Power $0.23 EPS vs $0.19e.
(TRMP) Trump Entertainment confirms retains Merrill Lynch to evaluate strategic alternatives.
(UNH) UnitedHealth is acquiring Sierra Health; UNH also reaffirmed $4.0 to $4.5 Billion for share buybacks.
(UWN) Nevada Gold -$0.06 EPS vs -$0.02e.
(VITA) Orthovita -$0.08 EPS vs -$0.07e.

Jon C. Ogg
March 12, 2007

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Half of America Still Feels Financially Exposed Despite 8% Jump in Security
David Beren |

Half of America Still Feels Financially Exposed Despite 8% Jump in Security
52% of Americans Are Building Wealth While Ignoring Their Greatest Risk
David Beren |

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

Continue Reading

Jon C. Ogg |

Elan’s Spin-Off Creates Buyout Hopes (ELN, BIIB, ALKS, PFE)

Elan Corporation, plc (NYSE: ELN) may be surging on news that it is going to spin off its drug research unit,…
Jon C. Ogg |

Top Active Trader Alert Stocks (APOL, BCS, RBS, BIIB, LVLT, QUIK, TSTY, TYC)

We have many stocks on the move this morning.  Our top pre-market movers for active traders and day traders alike…
7 Biopharma Companies That Destroyed Shareholders Last Week
Chris Lange |

7 Biopharma Companies That Destroyed Shareholders Last Week

Biotech companies that lost their way last week truly burned shareholders, whether it was due to ASCO, earnings or even…
Douglas A. McIntyre |

Biotech Business Daily (RIGL, BIIB, ARRY, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth…
Lee Jackson |

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the…
Jon C. Ogg |

The Abbott Break-Up Seems To Make Sense (ABT, BIIB, BMY)

Drug and medical stocks are not generally thought of as stocks hitting 52-week highs by the investing public.  So what…
Douglas A. McIntyre |

The Day In Biotech Stocks (January 28, 2008) (ACOR, BIIB, CELG, PHRM, CRXX, LIPD, MDVN, PCOP)

Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis.  This…
Biogen Stumbles Over Missed Mid-Stage Results
Chris Lange |

Biogen Stumbles Over Missed Mid-Stage Results

Shares of Biogen slumped early in Tuesday's session following the release of less-than-favorable top-line results from its mid-stage clinical study…
Picking Up the Pieces: How Biogen Is Dealing With Discontinued Alzheimer’s Trial
Chris Lange |

Picking Up the Pieces: How Biogen Is Dealing With Discontinued Alzheimer’s Trial

Biogen shares made a slight gain early on Monday after the firm made an SEC filing indicating that it will…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618